MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Ramiro Guerrero Purchases 78,239 Shares of Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ramiro Guerrero bought 78,239 shares of the business’s stock in a transaction on Thursday, August 27th. The shares were acquired at an average cost of $1.39 per share, for a total transaction of $108,752.21. Following the transaction, the director directly owned 689,081 shares in the company, valued at approximately $957,822.59. This trade represents a 12.81% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Ramiro Guerrero also recently made the following trade(s):

• On Friday, August 28th, Ramiro Guerrero bought 46,620 shares of MAIA Biotechnology stock. The stock was bought at an average price of $1.35 per share, for a total transaction of $62,937.00.
• On Wednesday, August 26th, Ramiro Guerrero bought 8,931 shares of MAIA Biotechnology stock. The shares were purchased at an average cost of $1.39 per share, with a total value of $12,414.09.
• On Monday, August 24th, Ramiro Guerrero purchased 1,794 shares of MAIA Biotechnology stock. The stock was acquired at an average price of $1.33 per share, with a total value of $2,386.02.
• On Thursday, August 20th, Ramiro Guerrero purchased 11,899 shares of MAIA Biotechnology stock. The stock was bought at an average cost of $1.37 per share, with a total value of $16,301.63.

MAIA Biotechnology Stock Performance

Shares of MAIA opened at $1.30 on Wednesday. MAIA Biotechnology, Inc. has a one year low of $0.87 and a one year high of $3.19. The stock has a market cap of $79.08 million, a P/E ratio of -2.10 and a beta of 0.25. The stock has a 50-day moving average of $1.37 and a two-hundred day moving average of $1.43.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). Analysts predict that MAIA Biotechnology, Inc. will post -0.54 EPS for the current fiscal year.

Institutional Trading of MAIA Biotechnology

A number of institutional investors have recently made changes to their positions in MAIA. Solas Capital Management LLC acquired a new position in shares of MAIA Biotechnology during the 2nd quarter worth approximately $4,364,000. Centric Wealth Management purchased a new stake in MAIA Biotechnology in the second quarter valued at $1,107,000. Cable Car Capital LP purchased a new stake in MAIA Biotechnology in the second quarter valued at $741,000. BlackRock Inc. acquired a new position in shares of MAIA Biotechnology in the 2nd quarter valued at $580,000. Finally, Corsair Capital Management L.P. purchased a new position in shares of MAIA Biotechnology during the 1st quarter worth $140,000. 5.65% of the stock is owned by institutional investors and hedge funds.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.